Drug Profile
Research programme: monoclonal antibody therapeutics - Iontas
Alternative Names: Anti-notch monoclonal antibodies - IontasLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator IONTAS
- Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Notch receptor antagonists; Notch signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer; Inflammation
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in United Kingdom
- 28 Sep 2020 No recent reports of development identified for research development in Inflammation in United Kingdom
- 03 Aug 2016 Monoclonal antibody therapeutics - Iontas is available for licensing as of 03 Aug 2016. http://www.iontas.co.uk/index.html